Is Trending Stock Illumina, Inc. (ILMN) a Buy Now?

Illumina (ILMN) has recently been on Zacks.com’s list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock’s performance in the near future.

Over the past month, shares of this genetic testing tools company have returned +6.2%, compared to the Zacks S&P 500 composite’s +10.8% change. During this period, the Zacks Medical – Biomedical and Genetics industry, which Illumina falls in, has gained 0.9%. The key question now is: What could be the stock’s future direction?

Although media reports or rumors about a significant change in a company’s business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate Revisions

Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company’s earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors’ interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Illumina is expected to post earnings of $0.40 per share for the current quarter, representing a year-over-year change of -72.4%. Over the last 30 days, the Zacks Consensus Estimate has changed -63.5%.

The consensus earnings estimate of $2.96 for the current fiscal year indicates a year-over-year change of -49.8%. This estimate has changed -31.6% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $4.38 indicates a change of +48% from what Illumina is expected to report a year ago. Over the past month, the estimate has changed -17.8%.

With an impressive externally audited track record, our proprietary stock rating tool — the Zacks Rank — is a more conclusive indicator of a stock’s near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Illumina.

The chart below shows the evolution of the company’s forward 12-month consensus EPS estimate:

12 Month EPS

12-month consensus EPS estimate for ILMN _12MonthEPSChartUrl

Projected Revenue Growth

Even though a company’s earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It’s almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company’s potential revenue growth is crucial.

For Illumina, the consensus sales estimate for the current quarter of $1.19 billion indicates a year-over-year change of +7.2%. For the current and next fiscal years, $4.74 billion and $5.61 billion estimates indicate +4.7% and +18.5% changes, respectively.

Last Reported Results and Surprise History

Illumina reported revenues of $1.16 billion in the last reported quarter, representing a year-over-year change of +3.2%. EPS of $0.57 for the same period compares with $1.87 a year ago.

Compared to the Zacks Consensus Estimate of $1.22 billion, the reported revenues represent a surprise of -4.73%. The EPS surprise was -9.52%.

Over the last four quarters, Illumina surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.

valuation

Without considering a stock’s valuation, no investment decision can be efficient. In predicting a stock’s future price performance, it’s crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company’s growth prospects.

Comparing the current value of a company’s valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values ​​helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on ), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Illumina is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values ​​of some of the valuation metrics that have driven this grade.

Bottom Line

The facts discussed here and much other information on Zacks.com might help determine whether or not it’s worthwhile paying attention to the market buzz about Illumina. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

Free: Top Stocks for the $30 Trillion Metaverse Boom

The metaverse is a quantum leap for the internet as we currently know it – and it will make some investors rich. Just like the internet, the metaverse is expected to transform how we live, work and play. Zacks has put together a new special report to help readers like you target big profits. The Metaverse – What is it? And How to Profit with These 5 Pioneering Stocks reveals specific stocks set to skyrocket as this emerging technology develops and expands.Download Zacks’ Metaverse Report now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Illumina, Inc. (ILMN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Leave a Reply

Your email address will not be published.